Skip to main content
. 2019 Oct 1;8(16):6955–6966. doi: 10.1002/cam4.2555

Figure 6.

Figure 6

Progression‐free survival according to progression of disease after first‐line immunochemotherapy (before/after 24 mo of treatment) prior to enrollment in the trial